Boston Trust Walden Corp Decreases Stock Holdings in Teleflex Incorporated (NYSE:TFX)

Boston Trust Walden Corp lowered its position in shares of Teleflex Incorporated (NYSE:TFX - Free Report) by 55.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 131,364 shares of the medical technology company's stock after selling 163,250 shares during the quarter. Boston Trust Walden Corp owned about 0.28% of Teleflex worth $18,153,000 as of its most recent SEC filing.

A number of other institutional investors have also bought and sold shares of TFX. Empowered Funds LLC bought a new stake in Teleflex during the fourth quarter valued at $259,000. Asset Management One Co. Ltd. boosted its position in Teleflex by 15.6% during the fourth quarter. Asset Management One Co. Ltd. now owns 19,233 shares of the medical technology company's stock valued at $3,453,000 after acquiring an additional 2,589 shares during the last quarter. Vontobel Holding Ltd. boosted its position in Teleflex by 21.9% during the fourth quarter. Vontobel Holding Ltd. now owns 1,393 shares of the medical technology company's stock valued at $248,000 after acquiring an additional 250 shares during the last quarter. Sanctuary Advisors LLC boosted its position in Teleflex by 28.2% during the fourth quarter. Sanctuary Advisors LLC now owns 6,251 shares of the medical technology company's stock valued at $1,143,000 after acquiring an additional 1,374 shares during the last quarter. Finally, Alberta Investment Management Corp bought a new stake in Teleflex during the fourth quarter valued at $2,011,000. Institutional investors own 95.62% of the company's stock.

Teleflex Stock Down 0.2%

NYSE TFX traded down $0.19 during trading hours on Monday, hitting $118.12. The company's stock had a trading volume of 447,529 shares, compared to its average volume of 629,175. Teleflex Incorporated has a 52 week low of $115.99 and a 52 week high of $249.91. The company has a market capitalization of $5.22 billion, a PE ratio of 37.26, a price-to-earnings-growth ratio of 1.85 and a beta of 1.10. The company has a current ratio of 2.28, a quick ratio of 1.32 and a debt-to-equity ratio of 0.44. The company's 50-day simple moving average is $125.44 and its two-hundred day simple moving average is $149.63.

Teleflex (NYSE:TFX - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.88 by $0.03. The firm had revenue of $700.67 million during the quarter, compared to analyst estimates of $699.37 million. Teleflex had a net margin of 4.96% and a return on equity of 14.73%. The company's revenue for the quarter was down 5.0% on a year-over-year basis. During the same quarter last year, the business posted $3.21 EPS. Research analysts anticipate that Teleflex Incorporated will post 13.98 EPS for the current fiscal year.

Teleflex Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 16th. Stockholders of record on Tuesday, May 20th were issued a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 1.15%. The ex-dividend date was Tuesday, May 20th. Teleflex's dividend payout ratio is currently 42.90%.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on TFX. Morgan Stanley cut their price objective on shares of Teleflex from $191.00 to $173.00 and set an "overweight" rating on the stock in a research report on Monday, May 5th. Needham & Company LLC reissued a "hold" rating on shares of Teleflex in a research report on Wednesday, March 12th. Royal Bank Of Canada cut their price objective on shares of Teleflex from $150.00 to $145.00 and set a "sector perform" rating on the stock in a research report on Friday, May 2nd. Piper Sandler reissued a "neutral" rating and set a $140.00 price objective (down previously from $255.00) on shares of Teleflex in a research report on Friday, February 28th. Finally, Truist Financial cut their price objective on shares of Teleflex from $140.00 to $137.00 and set a "hold" rating on the stock in a research report on Monday, May 5th. One analyst has rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $164.63.

Teleflex Company Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.